U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07159373) titled 'Better Options for Lymphatic Filariasis Treatment' on Aug. 26.
Brief Summary: The goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and adults living in communities where these diseases are common. The main questions it aims to answer are:
1. Does MoxDA clear infection in people with lymphatic filariasis ?
2. Does MoxDA cause any medical problems in infected and uninfected people?
Researchers will compare MoxDA with ivermectin given together with diethylcarbamaz...